Large-scale testing (Phase 3)UnknownNCT06140186What this trial is testingEfficacy and Safety of Timolol for TKI Induced ParonychiaWho this might be right forParonychia Queen Mary Hospital, Hong Kong 40
Testing effectiveness (Phase 2)UnknownNCT04318223What this trial is testingPalbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Consorzio Oncotech 168
Testing effectiveness (Phase 2)WithdrawnNCT00627627What this trial is testingEvaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWho this might be right forBreast Cancer MedImmune LLC 56
Large-scale testing (Phase 3)Study completedNCT02864251What this trial is testingNivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 367
Very early researchStudy completedNCT00863122What this trial is testingConcentration and Activity of Lapatinib in Vestibular SchwannomasWho this might be right forVestibular SchwannomaNF2Neurofibromatosis 2+2 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Testing effectiveness (Phase 2)Study completedNCT00045487What this trial is testingErlotinib in Treating Patients With Advanced Kidney CancerWho this might be right forKidney Cancer The University of Texas Health Science Center at San Antonio 41
Not applicableUnknownNCT00815971What this trial is testingMutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With ErlotinibWho this might be right forNon-Small Cell Lung Cancer Aarhus University Hospital 300
Testing effectiveness (Phase 2)Ended earlyNCT05636267What this trial is testingStudy of AK119 and AK112 With or Without Chemotherapy for NSCLC PatientsWho this might be right forNSCLC Akeso 59
Post-approval studies (Phase 4)WithdrawnNCT03988114What this trial is testingAbemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT04147351What this trial is testingA Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.Who this might be right forNSCLC Stage IIIB~IV National Taiwan University Hospital 22
Early research (Phase 1)Study completedNCT02060253What this trial is testingGanetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerWho this might be right forHER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479What this trial is testingSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis Zhejiang Cancer Hospital 45
Large-scale testing (Phase 3)Looking for participantsNCT06340568What this trial is testingA Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerWho this might be right forEndometrial Cancer BioNTech SE 480
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717What this trial is testingOsimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerWho this might be right forNon-Small Cell Lung Cancer Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Ended earlyNCT03222622What this trial is testingStudy of Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisWho this might be right forMild to Moderate Psoriasis Betta Pharmaceuticals Co., Ltd. 136
Very early researchNot Yet RecruitingNCT07498595What this trial is testingTILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLCWho this might be right forEGFR-TKI-resistant Non-Small Cell Lung Cancer Tianjin Medical University General Hospital 50
Early research (Phase 1)Study completedNCT00083057What this trial is testingGefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckWho this might be right forHead and Neck Cancer National Institutes of Health Clinical Center (CC) 30
Early research (Phase 1)Active Not RecruitingNCT05364073What this trial is testingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more ArriVent BioPharma, Inc. 160
Not applicableStudy completedNCT03059641What this trial is testingTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaWho this might be right forLung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more Geneplus-Beijing Co. Ltd. 300
Not applicableStudy completedNCT04370860What this trial is testingOptimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion VariantsWho this might be right forEGFR Exon 19 MutationTumor Progression National Taiwan University Hospital 1,000